Erez Livneh spoke about the potential of virus decoys to transform health care. Here's a snapshot into this moonshotter's background:
Erez spent a decade conducting and leading bioresearch programs in both academia and biotech companies. Today, he is the Founder and CEO of Vecoy Nanomedicines, a NanoPharma company that develops a new generation of nanomedicines for the treatment of HIV/AIDS, Hepatitis-C, Dengue Fever and other viral infections.
The nanoparticles so far suck up 97% of the viruses outside of the cells before they infect cells.
Vecoy Nanomedicines Ltd., a privately held company, incorporated in Israel in 2010, is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The Vecoy technology will fundamentally change the treatment of viral infections by administering novel nano-scale virus-traps that capture and destroy viruses.
Vecoy Nanomedicines Ltd., is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections.
Read more »
Erez spent a decade conducting and leading bioresearch programs in both academia and biotech companies. Today, he is the Founder and CEO of Vecoy Nanomedicines, a NanoPharma company that develops a new generation of nanomedicines for the treatment of HIV/AIDS, Hepatitis-C, Dengue Fever and other viral infections.
The nanoparticles so far suck up 97% of the viruses outside of the cells before they infect cells.
Vecoy Nanomedicines Ltd., a privately held company, incorporated in Israel in 2010, is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The Vecoy technology will fundamentally change the treatment of viral infections by administering novel nano-scale virus-traps that capture and destroy viruses.
Vecoy Nanomedicines Ltd., is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections.
Read more »